On 1st April 2018, Toujeo (insulin glargine 300 Units/mL) – a once-daily basal insulin was listed on the Pharmaceutical Benefits Scheme for the treatment of diabetes mellitus in adults.1,2 To understand how this treatment fits into the current paradigm, the limbic spoke with Coffs Harbour Endocrinologist and renowned Diabetes Specialist Dr Sultan Linjawi. “First of ...
It’s not apples and oranges when it comes to long-acting insulins
10 May 2018
Sponsored by Sanofi-aventis Australia Pty Ltd